Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International randomized phase II chemotherapy trial for recurrent and primary refractory Ewing sarcoma
2014-000259-99Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Jul 2014
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclophosphamide, topotecan, irinotecan, temozolomide, gemcitabine and 2 more in Ewing sarcoma (4 arms), sponsored by University of Birmingham. Primary endpoint: Objective response by RECIST. Status: unknown.
02
Drugs
cyclophosphamidetopotecanirinotecantemozolomidegemcitabine
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on 2014-000259-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000259-99.